MedTrace Logo

Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids

NCT06786780 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-03-26

No results posted yet for this study

Summary

This is a single-arm, single-center, open-label, Phase II study aimed at assessing the efficacy of organoids in predicting the response to radiotherapy and chemotherapy in cervical cancer

Conditions

Interventions

COMBINATION_PRODUCT

Drug: Cisplatin

Organoids were constructed prior to simultaneous radiochemical therapy

Sponsors & Collaborators

  • Chongqing University Cancer Hospital

    lead OTHER

Principal Investigators

  • Ling Long, PhD · Chongqing University Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-06-01
Completion
2026-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06786780 on ClinicalTrials.gov